Phage Therapy Market
Report ID: SQMIG35H2336
Report ID: SQMIG35H2336
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2336 |
Region:
Global |
Published Date: May, 2025
Pages:
187
|Tables:
124
|Figures:
77
Global Phage Therapy Market size was valued at USD 34.99 Million in 2024 and is poised to grow from USD 41.07 Million in 2025 to USD 148.22 Million by 2033, growing at a CAGR of 17.4% during the forecast period (2026–2033).
The global Phage Therapy Market is gaining more popularity as antibiotic resistance continues to rise and now forms a shadowing threat to global public health. The major growth drivers of this market include the increase in multidrug-resistant bacterial infections, greater investment into alternative antimicrobial therapy, and greater R&D activities from both the private and public sectors. Additionally, the therapy's high specificity against disease-causing bacteria, its preservation of the normal microbiome, and its absence of side effects make it an extremely appealing option. Government support through fast-track approval and grants is also spurring innovation and commercialization, particularly in North America and Europe.
On the restraint side, regulatory uncertainty and limited clinical evidence on large-scale effectiveness are still an issue. Although it has been applied for decades in parts of Eastern Europe, phage therapy lacks widespread global regulatory frameworks, making it difficult for pharmaceutical companies to navigate approval. The complexity of designing individualized bacteriophage cocktails for individual patients is added to by the logistic and cost-related barriers. Besides, there is limited large-scale clinical trials, which slows down mainstream medical adoption and insurance coverage. Further constraining scalability are the absence of standardized storage and manufacturing processes.
In the coming years, advancements in genome sequencing, synthetic biology, and personalized medicine will reduce the current barriers and enhance market access. The emergence of phage-based biotech ventures and the partnership between pharmaceutical companies and academia are signs of promising future trends. However, to achieve its full commercial potential, the industry needs to address the shortages in regulation, scale-up, and reputation. As the health system of the world increases its battle against superbugs, phage therapy may play a pivotal part in shaping the future of anti-infective therapy.
Clinical Trials Leading to Phage Therapy's Integration into the Mainstream?
Through March of 2023, there are 45 ClinicalTrials.gov-listed clinical trials for phage therapy, of which 25 are Phase I or Phase II and five are Phase III. These clinical trials are needed to ascertain phage therapy's safety and effectiveness, although phage therapy as yet has no FDA-approved drugs but does have potential in compassionate use applications.
Is Government Support Driving the Adoption of Phage Therapy in Asia-Pacific?
Asia-Pacific region accounts for 35% market share of the overall phage therapy market of the world, valued at USD 0.014 billion in 2024 and expected to rise at an 18.0% CAGR. This is because of the strong government support in countries like China, India, and South Korea, where there is investment in bacteriophage-based therapy in order to manage the increasing rate of antimicrobial resistance (AMR).
Market snapshot - 2026-2033
Global Market Size
USD 29.8 million
Largest Segment
Escherichia coli
Fastest Growth
Escherichia coli
Growth Rate
17.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Phage Therapy Market is segmented by Product, Type, Disease Indication, End User and region. Based on Product, the market is segmented into Escherichia coli, Staphylococcus aureus, Salmonella, Pseudomonas aeruginosa and Others. Based on Type, the market is segmented into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage and Others. Based on Disease Indication, the market is segmented into Urinary Tract Infections, Chronic Otitis, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis and Other Disease Indications. Based on End User, the market is segmented into Hospital & Clinics, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Escherichia coli (E. coli) dominates the phage therapy market since it is most engaged in urinary tract infections (UTIs) globally at 80–95%. Rising rates of antibiotic-resistant E. coli strains have driven the need for other drugs further. Thus, the U.S. Biomedical Advanced Research and Development Authority (BARDA) has partnered with Locus Biosciences, committing up to $93 million to fund the LBP-EC01 CRISPR-skewed phage therapy that targets E. coli-induced UTIs. This therapy had a 94% success rate against clinical E. coli strains in clinical trials. Such government-sponsored initiatives illustrate the prevalence of E. coli in phage therapy research.
Staphylococcus aureus is the most rapidly growing segment in the phage therapy market with its widespread occurrence and antibiotic resistance. S. is referred to by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) as a priority pathogen for phage research for the solution of antimicrobial resistance (AMR) issues. Clinical trials in America and Europe have shown the effectiveness of phage therapy against drug-resistant S. aureus infections. The Horizon 2020 program of the European Commission has also sponsored projects on phage application for S. aureus, indicative of international governmental interest.
Urinary Tract Infections (UTIs) reign supreme in the phage therapy market because they are highly prevalent globally and experience increasing antibiotic resistance. UTIs in 2019 represented more than 404 million cases worldwide, compared to 252 million in 1990, emphasizing a dramatic increase in incidence. Interestingly, 50–60% of females have at least one UTI during their lifetime. The World Health Organization documents that 1 in 5 E. coli-induced UTIs are currently less susceptible to routine antibiotics such as ampicillin and fluoroquinolones, making it more challenging to treat them. This increasing resistance highlights the necessity for alternative treatment options, with phage therapy emerging as a viable solution for treating UTIs effectively.
Skin and wound infections represent the most rapidly growing phage therapy segment because of their high worldwide prevalence and rising resistance to traditional antibiotics. In the U.S., chronic wounds affect nearly 2.5% of the population, and of these, surgical site infections account for a projected 110,800 cases per annum. Phage therapy is also emerging as an exciting therapy, particularly in the management of multidrug-resistant wound infections, e.g., diabetic foot ulcers and burn wounds. Government-funded research, such as the NIH R01AI169865 grant, is actively pursuing phage therapies for the treatment of biofilm-based infections. This is supported by global health initiatives that rank skin diseases as a leading public health issue, indicating the need for novel therapeutic methods.
To get detailed segments analysis, Request a Free Sample Report
North America has the highest percentage share of the overall phage therapy market, standing at around 40–45% of revenue. This can be explained by the large research efforts that receive government funding as well as by a strong health infrastructure. The National Institutes of Health (NIH), for example, has been actively supporting phage therapy research, such as programs like the R01AI169865 award, towards the creation of phage-based therapeutics for biofilm-related infections. Such investment highlights the area's emphasis on developing phage therapy as a potential alternative to conventional antibiotics.
The US dominates the phage therapy market due to large government spending and advanced research centers. Leading firms like Adaptive Phage Therapeutics have been prominent gainers, e.g., Adaptive Phage received a $5 million award by the Defense Health Agency for the clinical development of phage therapy in the treatment of diabetic foot osteomyelitis. Additionally, Intralytix has launched FDA-approved phage-based food items and is researching clinical trials for phage products as a potential human therapeutic agent, such as the use to treat Crohn's disease. Locus Biosciences based in North Carolina is designing CRISPR-modified phage drugs for treating antibiotic-resistant disease with next-generation gene editing capabilities.
Canada is turning out to be a vital role player increasingly, with companies like Cytophage Technologies making investments within specialist niches as a response to particular bacterial antagonists. Mexico also finds growing phage therapy market supported by strengthening trading terms and investing in technological research and development and has appealing chances both for native as well as overseas participants.
Asia-Pacific accounts for approximately 20–35% of the overall market and possesses the highest compound annual growth rate (CAGR) among all regions. China, India, and South Korea are spearheading this movement because of increased government support and increasing investments in the life sciences sector. These nations are focusing on developing bacteriophage-based therapies to address the increasing antimicrobial resistance (AMR) burden.
China leads the phage therapy market because of its rapidly growing biotechnology infrastructure and government support. The country is likely to account for 53.7% of the East Asian market share by 2034, with a market size of US$ 4.1 million in 2024 and a growth rate of 8% CAGR. Companies like Phagelux are busy developing new bacteriophage products to meet the increasing demand for healthier lifestyles.
Japan, with its robust pharmaceutical industry, is heavily involved in bacteriophage research. Japan's market is driven by technological innovation and enhanced interaction between academia and industry, which has resulted in the development of phage-based medicines.
Europe accounts for a significant portion of the phage therapy market, around 15% in 2024. The growth in Europe is driven by rising levels of multi-drug-resistant infections and cross-university and biotech company partnerships, especially in France, Germany, and the UK. Encouragement from the government towards alternative treatments further increases Europe's market share.
Germany takes the lead in phage therapy in Europe, supported by a robust regulatory framework that supports compassionate use and individualized therapy. Germany hosts several clinical trials and research initiatives related to phage solutions for multidrug-resistant infections.
France is in the vanguard of phage therapy, and players such as Pherecydes Pharma and Eligo Bioscience perform sophisticated research and clinical trials. The state complements this work through supply of funds and regulatory terms favoring the war on antibiotic-resistant bacteria.
The UK has built a strong phage therapy sector with companies like Fixed-Phage Limited producing new drugs. The National Health Service (NHS) and government-funded research programs promote the adoption of phage therapy in the clinic, geared towards countering the growing menace of antimicrobial resistance.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Antimicrobial Resistance
Increasing Incidence of Chronic Infections
Limited Clinical Data
Bacteriophage Specificity
Request Free Customization of this report to help us to meet your business objectives.
The highly competitive phage therapy market dynamics of the global stage are fueled by government funding, regulatory advancements, and collaboration strategies. Backed by large grants from the National Institutes of Health (NIH), Locus Biosciences and Adaptive Phage Therapeutics (APT) are spearheading the US towards developing individualized phage treatments. In Europe, Belgium has pioneered regulatory frameworks, such as magistral preparation, to make phage therapies accessible to the public. Moreover, the UK government is adding phage therapy to its 2024–2029 Antimicrobial Resistance National Action Plan. All these developments indicate a worldwide trend towards the integration of phage therapy into mainstream clinical practice.
Emerging Trends Shaping the Future of Phage Therapy
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected using Primary Exploratory Research backed by robust Secondary Desk research.
According to SkyQuest analysis, growing concerns about antimicrobial resistance, rising interest in targeted medicine, and advances in synthetic biology will remain key drivers for demand for phage therapy up to 2032. Yet, limited clinical evidence, regulatory ambiguity, and scalability challenges will tend to hinder mass adoption in the near term. Speeding up investment in precision biomanufacturing, increasing public-private partnerships, and the new AI-assisted phage matching platforms are making North America and Europe more and more dominant in this sector. Integration of CRISPR technology and expanding clinical trials for chronic bacterial infections are projected to open new growth avenues for industry players in the future.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 34.99 Million |
| Market size value in 2033 | USD 148.22 Million |
| Growth Rate | 17.4% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Phage Therapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Phage Therapy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Phage Therapy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Phage Therapy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
